In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation

[Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. today announced results of a pre-specified subanalysis of the Phase 3 ARISTOTLE trial in relation to patient age. ARISTOTLE was designed to evaluate the efficacy and safety of Eliquis compare more

View todays social media effects on BMY

View the latest stocks trending across Twitter. Click to view dashboard

See who Bristol is hiring next, click here to view